Table 15Indirect comparisons of withdrawals due to adverse events

DrugPlacebo rateRelative risk (95% confidence interval)
Compared with placebo
Duloxetine0.043.03 (1.82 to 5.03)
Pregabalin0.062.42 (1.89 to 3.08)
Gabapentin0.081.70 (1.10 to 2.62)
Lacosamide0.082.07 (1.24 to 3.47)
Lamotrigine0.111.75 (1.21 to 2.53)
Oxcarbazepine0.083.90 (2.18 to 6.97)
Topiramate0.082.91 (2.13 to 3.97)
Indirect comparison
Duloxetine vs. pregabalin1.25 (0.71 to 2.20)
Duloxetine vs. gabapentin1.78 (0.91 to 3.48)
Duloxetine vs. lacosamide1.46 (0.71 to 3.02)
Duloxetine vs. lamotrigine1.73 (0.92 to 3.24)
Pregabalin vs. gabapentin1.42 (0.87 to 2.34)
Pregabalin vs. lacosamide1.17 (0.66 to 2.07)
Pregabalin vs. lamotrigine1.38 (0.89 to 2.14)
Gabapentin vs. lacosamide0.82 (0.42 to 1.61)
Gabapentin vs. lamotrigine0.97 (0.55 to 1.71)
Lacosamide vs. lamotrigine1.18 (0.63 to 2.23)
Duloxetine vs. topiramate1.04 (0.57 to 1.89)
Pregabalin vs. topiramate0.83 (0.56 to 1.23)
Gabapentin vs. topiramate0.58 (0.34 to 0.99)
Lacosamide vs. topiramate0.71 (0.39 to 1.30)
Lamotrigine vs. topiramate0.60 (0.37 to 0.97)
Duloxetine vs. oxcarbazepine0.77 (0.36 to 1.68)
Pregabalin vs. oxcarbazepine0.62 (0.33 to 1.16)
Gabapentin vs. oxcarbazepine0.44 (0.21 to 0.90)
Lacosamide vs. oxcarbazepine0.53 (0.24 to 1.16)
Lamotrigine vs. oxcarbazepine0.45 (0.23 to 0.89)
Topiramate vs. oxcarbazepine0.75 (0.39 to 1.44)

From: Results

Cover of Drug Class Review: Neuropathic Pain
Drug Class Review: Neuropathic Pain: Final Update 1 Report [Internet].
Selph S, Carson S, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.